OBJECTIVES: To investigate whether a diagnosis of diminished ovarian reserve (DOR) in premenopausal years has adverse implications for skeletal health and quality of life. DESIGN: This was a cross-sectional study of infertile, albeit healthy, mid-reproductive-age women (younger than 42 y) attending an academic infertility practice. RESULTS: Eighty-nine women with varying causes of infertility were prospectively enrolled. Serum (cycle d 1-3) was collected for markers of ovarian reserve, bone metabolism, testosterone, and free androgen index. Bone mineral density (BMD) was assessed and categorized as low if the Z score was less than -1.0). Infertile women with DOR (n = 28) demonstrated significantly higher serum follicle-stimulating hormone levels (P < 0.001), lower müllerian-inhibiting substance (MIS) levels (P < 0.001), smaller ovarian dimensions (P < 0.05), lower testosterone levels (P = 0.035), lower free androgen index (P = 0.019), and enhanced bone metabolism (P = 0.003); although the prevalence of low BMD was higher in women with DOR who were younger than 41, this relationship was not of statistical significance (P = 0.106). Women younger than 41 years of age with DOR were significantly more likely to manifest disturbed sleep (P = 0.049) and acknowledge dissatisfaction with sexual intimacy (P = 0.004) compared with those with infertility and normal ovarian reserve. After adjustment for potential confounders, a diagnosis of DOR was significantly associated with low BMD, increased bone turnover, sexual dissatisfaction, and disturbed sleep. CONCLUSIONS: Our data suggest that DOR unmasked in the context of infertility evaluation has adverse implications for a woman's well-being that extend well beyond the thus far appreciated reproductive concerns. A decline in ovarian hormones, specifically estrogen and testosterone, concomitant with DOR may be hypothesized as a mechanism that can explain the observed multisystem ramifications of DOR including increased bone turnover, low BMD, sexual distress, and disturbed sleep.
OBJECTIVES: To investigate whether a diagnosis of diminished ovarian reserve (DOR) in premenopausal years has adverse implications for skeletal health and quality of life. DESIGN: This was a cross-sectional study of infertile, albeit healthy, mid-reproductive-age women (younger than 42 y) attending an academic infertility practice. RESULTS: Eighty-nine women with varying causes of infertility were prospectively enrolled. Serum (cycle d 1-3) was collected for markers of ovarian reserve, bone metabolism, testosterone, and free androgen index. Bone mineral density (BMD) was assessed and categorized as low if the Z score was less than -1.0). Infertile women with DOR (n = 28) demonstrated significantly higher serum follicle-stimulating hormone levels (P < 0.001), lower müllerian-inhibiting substance (MIS) levels (P < 0.001), smaller ovarian dimensions (P < 0.05), lower testosterone levels (P = 0.035), lower free androgen index (P = 0.019), and enhanced bone metabolism (P = 0.003); although the prevalence of low BMD was higher in women with DOR who were younger than 41, this relationship was not of statistical significance (P = 0.106). Women younger than 41 years of age with DOR were significantly more likely to manifest disturbed sleep (P = 0.049) and acknowledge dissatisfaction with sexual intimacy (P = 0.004) compared with those with infertility and normal ovarian reserve. After adjustment for potential confounders, a diagnosis of DOR was significantly associated with low BMD, increased bone turnover, sexual dissatisfaction, and disturbed sleep. CONCLUSIONS: Our data suggest that DOR unmasked in the context of infertility evaluation has adverse implications for a woman's well-being that extend well beyond the thus far appreciated reproductive concerns. A decline in ovarian hormones, specifically estrogen and testosterone, concomitant with DOR may be hypothesized as a mechanism that can explain the observed multisystem ramifications of DOR including increased bone turnover, low BMD, sexual distress, and disturbed sleep.
Authors: Jacqueline D Kloss; Michael L Perlis; Jessica A Zamzow; Elizabeth J Culnan; Clarisa R Gracia Journal: Sleep Med Rev Date: 2014-10-18 Impact factor: 11.609
Authors: Susan E Appt; Thomas B Clarkson; Patricia B Hoyer; Nancy D Kock; Amanda K Goode; M Christina May; Joseph T Persyn; Neal K Vail; Kelly F Ethun; Haiying Chen; Nivedita Sen; Jay R Kaplan Journal: Comp Med Date: 2010-10 Impact factor: 0.982
Authors: Sydney Kaye Willis; Elizabeth Elliott Hatch; Amelia Kent Wesselink; Kenneth Jay Rothman; Ellen Margrethe Mikkelsen; Lauren Anne Wise Journal: Fertil Steril Date: 2019-04-12 Impact factor: 7.329
Authors: Mette W Christensen; David L Keefe; Fang Wang; Christine S Hansen; Isaac J Chamani; Carolyn Sommer; Mette Nyegaard; Palle D Rohde; Anders L Nielsen; Jonas Bybjerg-Grauholm; Ulrik S Kesmodel; Ulla B Knudsen; Kirstine Kirkegaard; Hans Jakob Ingerslev Journal: J Assist Reprod Genet Date: 2021-10-01 Impact factor: 3.412
Authors: Gioia M Guerrieri; Pedro E Martinez; Summer P Klug; Nazli A Haq; Vien H Vanderhoof; Deloris E Koziol; Vaishali B Popat; Sophia N Kalantaridou; Karim A Calis; David R Rubinow; Peter J Schmidt; Lawrence M Nelson Journal: Menopause Date: 2014-09 Impact factor: 2.953
Authors: Lisa M Pastore; Mindy S Christianson; James Stelling; William G Kearns; James H Segars Journal: J Assist Reprod Genet Date: 2017-10-02 Impact factor: 3.412